PlaqueTec was formed in 2008 within Papworth Hospital in Cambridge (UK), as a spinout from PA Consulting. With funding from Ipex Capital and guidance from a strong network of scientific advisors and clinicians, the company has developed the first-of-its-kind PlaqueTec Liquid Biopsy System™ (LBS) a revolutionary technology that facilitates the identification and collection of biomarker samples from vulnerable plaque within coronary arteries, providing clinically valuable information pertaining to vascular function, inflammation, and coronary plaque progression. Since 2012, PlaqueTec has validated its LBS device in two clinical studies and identified numerous biomarkers that are associated with CAD. The company is using these biomarkers to build a database to provide a better understanding of CAD that can be used by clinicians, researchers, and biopharmaceutical companies to conduct translational research and develop next-generation personalized therapies. The PlaqueTec LBS received a CE Mark in July 2014 for use in the EU.